TABLE 5-continued

The Activity of MJK-006, -008 and -004 Compounds

Compound	HDAC4	Bladder ca	HDAC9	Crohn's
 MJK006	+	+	++++	++++
 MJK008	+	+	++++	++++

REFERENCES

[0238] (1) Mai, A.; Massa, S.; Pezzi, R.; Simeoni, S.; Rotili, D.; Nebbioso, A.; Scognamiglio, A.; Altucci, L.; Loidl, P.; Brosch, G. *J Med. Chem.* 2005, 48, 3344-3353.

[0239] (2) Fleming, C. L.; Ashton, T. D.; Gaur, V.; McGee, S. L.; Pfeffer, F. M. *J. Med. Chem.* 2014, 57, 1132-1135.

[0240] (3) Hong, B. T.; Chen, C. L.; Fang, J. M.; Tsai, K. C.; Wang, S. Y.; Huang, W. I.; Cheng, Y. S. E.; Wong, C. H. *Bioorg. Med. Chem.* 2014, 22, 6647-6654.

INCORPORATION BY REFERENCE

[0241] All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

EQUIVALENTS

[0242] While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification and the claims below. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.

1. A compound of formula I, or a pharmaceutically acceptable salt thereof:

(I)



wherein:

R^1 is aryl or heteroaryl; and

R^2 is alkyl.

2. The compound of claim **1**, wherein the compound is not



3. The compound of claim **1**, wherein R^1 is 6-membered aryl or 5- to 6-membered heteroaryl.

4. The compound of claim **1**, wherein R^1 is phenyl optionally substituted with alkoxy, such as methoxy, or halo, such as chloro.

5. The compound of claim **4**, wherein R^1 is substituted at the 2-position with alkoxy, such as methoxy, or halo, such as chloro.

6. The compound of claim **1**, wherein R^1 is pyrrolyl and is optionally substituted at the N-position with alkyl, such as methyl.

7. The compound of claim **1**, wherein R^1 is pyridinyl, pyrazinyl, thiophenyl, or furanyl.

8. The compound of claim **7**, wherein R^1 is pyridinyl, such as pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl.

9. The compound of claim **7**, wherein R^1 is thiophenyl, such as thiophen-3-yl or thiophen-2-yl.

10. The compound of claim **1**, wherein: R^2 is methyl.

11. A pharmaceutical composition comprising a compound of claim **1** and a pharmaceutically acceptable excipient.

12. A method of inhibiting an HDAC enzyme, such as an HDAC Class IIA enzyme, in a subject, comprising administering to the subject a compound or composition of claim **1**.

13. The method of claim **12**, wherein R^1 is pyridinyl, such as pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl.

14. The method of claim **12**, wherein R^1 is thiophenyl, such as thiophen-3-yl or thiophen-2-yl.